GlobeNewswire Inc.··Hagens BermanSLNO Stock Plunges 27% on Safety Concerns: Class Action Lawsuit Targets Soleno Therapeutics
Soleno Therapeutics faces class action lawsuit over safety concerns and inflated metrics for flagship drug VYKAT™ XR. Stock plunged 27% following August short report and November earnings disappointment.
SLNOsecurities fraudclass action lawsuit